Vaccine immunity in patients with 22q11.2 microdeletion syndrome.

ABSTRACT:

Background

Patients with microdeletion 22q11.2 syndrome (MDS) exhibit immunological defects, characterized by abnormalities in the development of the thymus, which plays a crucial role in T-cell maturation and immune response. As a result, these patients may have impaired adaptive immunity, with decreased responses to vaccination.

Methods

This was a prospective observational study. Vaccine serology (tetanus, diphtheria, Haemophilus influenzae type b for children <5 years, measles, varicella, hepatitis A and B, and SARS-CoV-2) and immune parameters were assessed in MDS patients aged between 1 and 25 years followed in Geneva between February 2022 and April 2023.

Results

41 MDS patients were included. The median age was 13 years old. Most of them reported recurrent otiti

SUBMITTER: Farpour L 

PROVIDER: S-EPMC12813736 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature